In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on ProQR (PRQR – Research Report), with a price target of $2.50. The company's shares closed last Wednesday at $0.79. According to TipRanks.com, Nakae is a 4-star analyst with an average return of 10.4% and a 42.7% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Mountain Crest Acquisition II, and Arrowhead Pharmaceuticals. Currently, the analyst consensus on ProQR is a Moderate Buy with an average price target of $3.25, a 261.1% upside from current levels.
https://www.tipranks.com/news/blurbs/chardan-capital-remains-a-buy-on-proqr-prqr?utm_source=advfn.com&utm_medium=referral
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more ProQR Therapeutics NV Charts.
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more ProQR Therapeutics NV Charts.